BD - Earth day 2024

Biosense Webster Launches the OCTARAY™ Mapping Catheter with TRUEref™ Technology

Wednesday, September 07, 2022

Biosense Webster, Inc., a subsidiary of Johnson & Johnson MedTech‡, introduces the OCTARAY™ Mapping Catheter with TRUEref™ Technology, powered by the CARTO™ 3 Version 7 System. Specifically designed for mapping cardiac arrhythmias, including atrial fibrillation (AFib), this catheter offers enhanced features to improve efficiency and accuracy during ablation procedures. With eight splines and improved electrode spacing, the OCTARAY™ Mapping Catheter allows for shorter mapping times and overall procedure durations. AFib affects millions of people worldwide and can lead to severe complications if left untreated. Catheter ablation, facilitated by the OCTARAY™ Mapping Catheter, is a safe and effective method to correct abnormal heart rhythms. Featuring TRUEref™ Technology, this catheter reduces farfield signals and provides precise mapping information for targeted therapy. With its advanced capabilities, including increased surface area coverage and improved signal quality, the OCTARAY™ Mapping Catheter is a valuable addition to the tools available for electrophysiologists. This innovative mapping catheter is now available in the U.S. and EMEA, having received CE marking and 510(k) clearance from the FDA.

Healthcare CEO & Executive Strategy SummitHealthcare CNO SummitHealthcare CMO SummitHealthcare CFO, Financial Strategy & Revenue Cycle SummitThe Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation Summit